Intellia Therapeutics Inc.
NTLA | NASDAQ
$12.61
+$0.39 (+3.19%)
Sep 22, 2026, 1:23 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 7.66M | 15.05M | 23.02M | 13.78M | 14.25M | 16.63M | 12.87M | 9.11M | 6.96M | 28.94M | -1.92M | 11.99M | 13.59M | 12.61M | 13.57M | 13.27M | 14.03M | 11.25M | 12.85M | 7.2M | 6.55M | 6.45M |
Cost of Revenue | n/a | 2.2M | 6.02M | 78.95M | 80.53M | n/a | 116.88M | 109.17M | 2.6M | 2.51M | 2.47M | 2.29M | 115.28M | 97.12M | 100.03M | 96.65M | 90.2M | 133.1M | 71.16M | 60.49M | 58.88M | 39.28M |
Gross Profit | n/a | 12.85M | 17M | -65.17M | -66.29M | 16.63M | -104M | -100.06M | 4.36M | 26.42M | -4.38M | 9.7M | -101.68M | -84.51M | -86.46M | -83.39M | -76.17M | -121.84M | -58.31M | -53.28M | -52.33M | -32.83M |
Operating Income | n/a | -100.53M | -98.71M | -111.48M | -110M | -120.81M | -136.45M | -144.77M | -139.04M | -114M | -139.89M | -131.11M | -132.33M | -111.96M | -110.09M | -105.53M | -98.3M | -144.25M | -80.42M | -71.99M | -69.02M | -46.43M |
Interest Income | 5.8M | 5.21M | 6.48M | 6.71M | 7.4M | 8.6M | 10.63M | 12.12M | 12.42M | 12.63M | 12.46M | 12.74M | 12.65M | 11.98M | 5.35M | 1.95M | 703K | 540K | 503K | 349K | 211K | 220K |
Pretax Income | -106.63M | -96.23M | -95.79M | -101.32M | -101.26M | -114.33M | -128.9M | -135.71M | -146.98M | -107.44M | -132.16M | -122.22M | -123.68M | -103.13M | -113.41M | -113.23M | -100.68M | -146.87M | -81.24M | -71.64M | -68.81M | -46.21M |
Net Income | -106.63M | -96.23M | -95.79M | -101.32M | -101.26M | -114.33M | -128.9M | -135.71M | -146.98M | -107.44M | -132.16M | -122.22M | -123.68M | -103.13M | -113.41M | -113.23M | -100.68M | -146.87M | -81.24M | -71.64M | -68.81M | -46.21M |
Selling & General & Admin | 37.82M | 34.84M | 33.08M | 46.31M | 43.71M | 29.01M | 32.44M | 44.71M | 31.79M | 31.09M | 28.99M | 29.4M | 30.65M | 27.45M | 23.63M | 22.15M | 22.13M | 22.4M | 22.11M | 18.71M | 16.68M | 13.59M |
Research & Development | 82.6M | 80.74M | 88.65M | 94.75M | 97.04M | 108.43M | 116.88M | 123.38M | 111.61M | 109.34M | 108.98M | 113.7M | 115.28M | 97.12M | 100.03M | 96.65M | 90.2M | 133.1M | 71.16M | 60.49M | 58.88M | 39.28M |
Other Expenses | n/a | -2.2M | -6.02M | -94.75M | -97.04M | n/a | -116.88M | -123.38M | n/a | n/a | -2.47M | -2.29M | -115.28M | -97.12M | -100.03M | -96.65M | -90.2M | -133.1M | -71.16M | -60.49M | -58.88M | -39.28M |
Operating Expenses | 120.42M | 113.38M | 115.71M | 46.31M | 43.71M | 137.43M | 32.44M | 44.71M | 143.4M | 140.43M | 135.51M | 140.81M | 30.65M | 27.45M | 23.63M | 22.15M | 22.13M | 22.4M | 22.11M | 18.71M | 16.68M | 13.59M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | 15.8M | 16.5M | n/a | n/a | 14.21M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 115.58M | 121.73M | 125.26M | 124.24M | 137.43M | 149.32M | 153.88M | 146M | 142.94M | 137.98M | 143.1M | 145.93M | 124.56M | 123.66M | 118.8M | 112.33M | 155.5M | 93.27M | 79.2M | 75.57M | 52.87M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 133.48M | 118.49M | 108.38M | 110.19M | 103.73M | 103.5M | 101.86M | 101M | 96.98M | 95.5M | 90.46M | 88.65M | 88.19M | 87.77M | 81.22M | 76.05M | 75.82M | 74.75M | 74.43M | 73.71M | 68.16M | 67.18M |
Shares Outstanding (Diluted) | 133.48M | 118.49M | 108.38M | 110.19M | 103.73M | 103.5M | 101.86M | 101M | 96.98M | 95.5M | 90.46M | 88.65M | 88.19M | 87.77M | 81.22M | 76.05M | 75.82M | 74.75M | 74.43M | 73.71M | 68.16M | 67.18M |
EPS (Basic) | -0.80 | -0.81 | -0.83 | -0.92 | -0.98 | -1.10 | -1.27 | -1.34 | -1.52 | -1.12 | -1.46 | -1.38 | -1.40 | -1.17 | -1.40 | -1.49 | -1.33 | -1.96 | -1.09 | -0.97 | -1.01 | -0.69 |
EPS (Diluted) | -0.80 | -0.81 | -0.83 | -0.92 | -0.98 | -1.10 | -1.27 | -1.34 | -1.52 | -1.12 | -1.46 | -1.38 | -1.40 | -1.17 | -1.40 | -1.49 | -1.33 | -1.96 | -1.09 | -0.97 | -1.01 | -0.69 |
EBITDA | n/a | -94.03M | -95.41M | -96.39M | -98.78M | -111.83M | -126.33M | -133.1M | -144.38M | -104.92M | -129.7M | -119.93M | -121.51M | -101.08M | -111.38M | -111.28M | -98.84M | -145.12M | -79.36M | -69.86M | -67.17M | -44.83M |
EBIT | n/a | -96.23M | -95.79M | -101.32M | -101.26M | -114.33M | -128.9M | -135.71M | -146.98M | -107.44M | -132.16M | -122.22M | -123.68M | -103.13M | -113.41M | -113.23M | -100.68M | -146.87M | -81.24M | -71.64M | -68.81M | -46.43M |
Depreciation & Amortization | n/a | 2.2M | 377K | 4.94M | 2.47M | 2.5M | 2.57M | 2.61M | 2.6M | 2.51M | 2.47M | 2.29M | 2.17M | 2.05M | 2.03M | 1.95M | 1.84M | 1.75M | 1.88M | 1.79M | 1.63M | 1.59M |
Add to Watchlist
Select watchlists to add or remove NTLA